Prognosis and Outcome of Small (≤1 cm), Node-Negative Breast Cancer on the Basis of Hormonal and HER-2 Status (Q35583711)

9 August 2017

title

Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status (English)

1 reference

9 August 2017

Prognosis and Outcome of Small (≤1 cm), Node-Negative Breast Cancer on the Basis of Hormonal and HER-2 Status (English)

1 reference

Crossref

https://api.crossref.org/works/10.1634/THEONCOLOGIST.2010-0036

29 July 2024

Edith A Perez

1 reference

9 August 2017

Judy C Boughey

1 reference

9 August 2017

Surabhi Amar

1 reference

9 August 2017

Winston Tan

1 reference

9 August 2017

Ann E. McCullough

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

29 July 2024

Xochiquetzal J. Geiger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

29 July 2024

Judy C. Boughey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

29 July 2024

Rebecca B. McNeil

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

29 July 2024

Kyle E. Coppola

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

29 July 2024

Sarah A. McLaughlin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

29 July 2024

Frances M. Palmieri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

29 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20930097

29 July 2024

publication date

7 October 2010

1 reference

full work available at URL

9 August 2017

http://theoncologist.alphamedpress.org/content/15/10/1043.full.pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

http://intl-theoncologist.alphamedpress.org/cgi/content/full/15/10/1043

29 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

http://intl-theoncologist.alphamedpress.org/cgi/content/abstract/15/10/1043

29 July 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

http://intl-theoncologist.alphamedpress.org/cgi/reprint/15/10/1043.pdf

29 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20930097/?tool=EBI

29 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20930097/pdf/?tool=EBI

29 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

https://europepmc.org/articles/PMC3227894

29 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

https://europepmc.org/articles/PMC3227894?pdf=render

29 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

https://doi.org/10.1634/theoncologist.2010-0036

29 July 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930097

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2010-0036

29 July 2024

1 reference

Crossref

https://api.crossref.org/works/10.1634/THEONCOLOGIST.2010-0036

https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.2010-0036

29 July 2024

1 reference

Crossref

https://api.crossref.org/works/10.1634/THEONCOLOGIST.2010-0036

https://academic.oup.com/oncolo/article-pdf/15/10/1043/41842876/oncolo_15_10_1043.pdf

29 July 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.2010-0036

29 July 2024

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

1043-1049

1 reference

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

Prognostic markers in triple-negative breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

The distinctive nature of HER2-positive breast cancers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

c-erbB-2 amplification in node-negative human breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227894

A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20930097

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20930097

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

1 reference

9 August 2017

1 reference

9 August 2017

1 reference